Abstract: The present invention provides methods and dosing regimens for treating and preventing ocular disorders using c-raf antisense oligonucleotides, alone or in combination with other agents.
Abstract: The present invention is directed to combination therapies and drug delivery devices comprising antisense oligonucleotides directed to a raf gene. In certain embodiments, the combination therapies and drug delivery devices of the present invention are used to treat cancers and ocular diseases.